WPRIM Management System> DCMS> Journal of Gynecologic Oncology> > 23

Volume: 23

1. Radiation sigmoiditis mimicking sigmoid colon cancer after radiation therapy for cervical cancer: the implications of three-dimensional image-based brachytherapy planning. Page:197—200
2. The effects of selenium on tumor growth in epithelial ovarian carcinoma. Page:190—196
3. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. Page:182—189
4. Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. Page:175—181
5. Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer. Page:168—174
6. Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement. Page:159—167
7. Tumor volume and lymphovascular space invasion as a prognostic factor in early invasive adenocarcinoma of the cervix. Page:153—158
8. Cervical cancer prevention program in Jakarta, Indonesia: See and Treat model in developing country. Page:147—152
9. Awareness of cervical cancer screening among nursing staff in a tertiary institution of rural India. Page:141—146
10. 10th International Conference of ACOS, June 13-15 2012. Page:139—140
11. Screening of uterine cervical cancer in low-resource settings. Page:137—138
12. Telesurgery is promising but still need proof through prospective comparative studies. Page:134—135
13. HE4, CA-125, and cystic ovarian mass. Page:133—133
14. Successful pregnancy following transfer of frozen-thawed embryos in a patient with pseudomyxoma peritonei who underwent peritonectomy and bilateral oophorectomy. Page:129—132
15. Early diagnosis of malignant-transformed ovarian mature cystic teratoma: fat-suppressed MRI findings. Page:125—128
16. Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. Page:120—124
17. Photodynamic therapy for breast cancer in a BALB/c mouse model. Page:115—119
18. Does ductal lavage assert its role as a noninvasive diagnostic modality to identify women at low risk of breast cancer development?. Page:110—114
19. Changes in biologic markers of oxidative stress and plasma endotoxin levels in gynecologic cancer patients treated with pelvic radiotherapy: a pilot study. Page:103—109
20. Cut-off value of D-dimer for prediction of deep venous thrombosis before treatment in ovarian cancer. Page:98—102
21. Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. Page:91—97
22. Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer. Page:86—90
23. Unusual involvement of cervix and vulva in a case of chronic lymphocytic leukemia. Page:205—206
24. Successful term pregnancies after laparoscopic excision of poorly differentiated Sertoli-Leydig cell tumor of the ovary. Page:201—204
25. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. Page:274—281
26. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. Page:265—273
27. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. Page:274—281
28. Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. Page:257—264
29. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. Page:265—273
30. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. Page:251—256
31. Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. Page:257—264
32. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. Page:242—250
33. How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. Page:251—256
34. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. Page:235—241
35. Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea. Page:242—250
36. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. Page:226—234
37. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. Page:235—241
38. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. Page:217—225
39. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. Page:226—234
40. TGCS's Annual Meeting, August 10-12, 2012. Page:215—216
41. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. Page:217—225
42. Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN). Page:213—214
43. TGCS's Annual Meeting, August 10-12, 2012. Page:215—216
44. Emerging concept of tailored lymphadenectomy in endometrial cancer. Page:210—212
45. Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN). Page:213—214
46. Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?. Page:207—209
47. Emerging concept of tailored lymphadenectomy in endometrial cancer. Page:210—212
48. Optimal therapy for IB2 and IIA2 cervical cancer: surgery or chemoradiotherapy?. Page:207—209
49. Book Review: The emperor of all maladies: a biography of cancer. Page:291—292
50. Sweet's syndrome: a cutaneous harbinger of ovarian carcinoma. Page:288—290
51. New insights into cervical cancer screening. Page:282—287
52. Minichromosome maintenance 7 protein is a reliable biological marker for human cervical progressive disease. Page:11—15
53. Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media. Page:5—10
54. 9th Korea-Japan Gynecologic Cancer Joint Meeting. Page:3—4
55. The Journal of Gynecologic Oncology and the Asian Society of Gynecologic Oncology: the history, the present and the future. Page:1—2
56. Indications for endoscopy according to the revised FIGO staging for cervical cancer after MRI and CT scanning. Page:80—85
57. How to make the best strategy to manage thromboembolism in ovarian cancer?. Page:78—79
58. Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. Page:75—77
59. Hereditary portion as an initial genetic approach in gynecologic cancer: synchronous tumor of ovary and endometrium. Page:72—73
60. Late presentation of metastatic smooth muscle neoplasm of the uterus with low malignant potential. Page:69—71
61. Complete biologic response to taxane based chemotherapy confirmed by 18FFDG PET/CT and surgery in a cancer of unknown primary site. Page:65—68
62. Major clinical research advances in gynecologic cancer in 2011. Page:53—64
63. Gastrointestinal stromal tumors as an incidental finding in patients with a presumptive diagnosis of ovarian cancer. Page:48—52
64. Characteristics of thyroid incidentalomas detected by pre-treatment 18FFDG PET or PET/CT in patients with cervical cancer. Page:43—47
65. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. Page:35—42
66. Preoperative 18FFDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. Page:28—34
67. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. Page:22—27
68. Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009. Page:16—21